Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Anterogen Co. Ltd. is currently active in the Biotechnology & Pharmaceuticals technology area, with a portfolio that includes 1 pending office action. This action is being handled by a distinct examiner, indicating a centralized prosecution effort for the company's current filings. The workload is also limited to a distinct art unit, which means the applicant is interacting with a specific group of technical experts at the patent office.
The busiest examiner for this portfolio is LANDAU, SHARMILA GOLLAMUDI, who is overseeing 1 busiest_examiner_pending office action. Because this examiner is the only one currently reviewing the company's pending matters, the applicant can focus their strategy on addressing this individual's specific concerns. This direct relationship can lead to a more efficient prosecution process compared to portfolios managed by multiple examiners.
For a patent practitioner, the presence of 1 pending office action under LANDAU, SHARMILA GOLLAMUDI suggests a low level of complexity in the current biotechnology filings. There is no need to coordinate between different examiner perspectives or art unit requirements. Instead, the company can prioritize its resources on resolving the specific issues raised in the pending matter currently under review.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LANDAU, SHARMILA GOLLAMUDI | 1 | 11.1% | +4.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18158215 | MESENCHYMAL STEM CELL-HYDROGEL-BIODEGRADABLE OR MESENCHYMAL STEM CELL-HYDROGEL-UNDEGRADABLE SUPPORT COMPOSITION FOR SKIN REGENERATION OR WOUND HEALING | LANDAU, SHARMILA GOLLAMUDI | — |
| Art Unit | Apps |
|---|---|
| 1653 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18158215 | MESENCHYMAL STEM CELL-HYDROGEL-BIODEGRADABLE OR MESENCHYMAL STEM CELL-HYDROGEL-UNDEGRADABLE SUPPORT COMPOSITION FOR SKIN REGENERATION OR WOUND HEALING | LANDAU, SHARMILA GOLLAMUDI | 1653 | §103 | Non-Final OA | — | Pending | Jan 23, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAnterogen Co. Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Sharmila Gollamudi Landau has the most, with 1 of Anterogen Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.